These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9258086)

  • 1. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer.
    Schmetter BS; Habicht KK; Lamm DL; Morales A; Bander NH; Grossman HB; Hanna MG; Silberman SR; Butman BT
    J Urol; 1997 Sep; 158(3 Pt 1):801-5. PubMed ID: 9258086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid detection of bladder cancer: a comparative study of point of care tests.
    Johnston B; Morales A; Emerson L; Lundie M
    J Urol; 1997 Dec; 158(6):2098-101. PubMed ID: 9366321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of screening methods in the detection of bladder cancer.
    Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
    J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further study of fibrinogen degradation products in bladder cancer detection.
    Wajsman Z; Williams PD; Greco J; Murphy GP
    Urology; 1978 Dec; 12(6):659-61. PubMed ID: 741544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer.
    Tsihlias J; Grossman HB
    Urol Clin North Am; 2000 Feb; 27(1):39-46. PubMed ID: 10696243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The usefulness of urinary FDP in the diagnosis of bladder cancer: comparison with NMP22, BTA and cytology].
    Oeda T; Manabe D
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):1-5. PubMed ID: 11235137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients.
    Topsakal M; Karadeniz T; Anaç M; Dönmezer S; Besisik A
    Eur Urol; 2001 Mar; 39(3):287-91. PubMed ID: 11275721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests?
    Pirtskalaishvili G; Konety BR; Getzenberg RH
    Postgrad Med; 1999 Nov; 106(6):85-6, 91-4. PubMed ID: 10576004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The investigation on early diagnosis of the bladder tumor. I: A study on urinary cytology and urinary fibrin/fibrinogen degradation products (FDP) assay in patient with bladder tumor (author's transl)].
    Tanahashi T
    Nihon Hinyokika Gakkai Zasshi; 1979 May; 70(5):553-62. PubMed ID: 470263
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparative analysis of rapid urine tests for the diagnosis of upper urinary tract malignancy.
    Siemens DR; Morales A; Johnston B; Emerson L
    Can J Urol; 2003 Feb; 10(1):1754-8. PubMed ID: 12625854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary fibrinogen degradation products (FDP) in bladder cancer.
    Martínez-Piñeiro JA; Pertusa C; Maganto E; Zancajo VG; Magallon M; Losada G; Ortega F
    Eur Urol; 1978; 4(5):348-50. PubMed ID: 710466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
    Lokeshwar VB; Soloway MS
    J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma.
    Jayachandran S; Unni Mooppan MM; Wax SH; Kim H
    J Urol; 1984 Jul; 132(1):21-3. PubMed ID: 6726955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer.
    Jeong S; Park Y; Cho Y; Kim YR; Kim HS
    Clin Chim Acta; 2012 Dec; 414():93-100. PubMed ID: 22944145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A correlative study on urinary cytology and FDP with cystoscopy and pathology in the urinary bladder cancers.
    Tanahashi T; Matsumura Y; Ohmori H; Tanaka T
    Acta Med Okayama; 1978 Jun; 32(2):139-46. PubMed ID: 150199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary fibrin/fibrinogen degradation products in transitional cell carcinoma of the bladder.
    Ewing R; Tate GM; Hetherington JW
    Br J Urol; 1987 Jan; 59(1):53-8. PubMed ID: 3828688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder cancer. II. Molecular aspects and diagnosis.
    Kausch I; Böhle A
    Eur Urol; 2001 May; 39(5):498-506. PubMed ID: 11464029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)].
    Tanahashi T
    Nihon Hinyokika Gakkai Zasshi; 1980 Sep; 71(9):1047-54. PubMed ID: 7193258
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of biological markers in bladder cancer.
    Wajsman Z; Merrin CE; Chu TM; Moore RH; Murphy GP
    J Urol; 1975 Dec; 114(6):879-93. PubMed ID: 1195467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine based markers of urological malignancy.
    Konety BR; Getzenberg RH
    J Urol; 2001 Feb; 165(2):600-11. PubMed ID: 11176445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.